Oncotype DX Study Underscores Challenges for Patients, Doctors in Interpreting Genomic Test Results
March 10, 2010
Oncotype DX Study Underscores Challenges for Patients, Doctors in Interpreting Genomic Test Results
Around one-third of the women in the study said they comprehended "a moderate amount or less" of the discussion of their Oncotype DX test results with their physician; approximately 25 percent of participants reported that they felt "distressed" when receiving their test results.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter - Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
May 18, 2011 / Pharmacogenomics Reporter - Genomic Health Nets Second Validation Study Publication for Oncotype DX Colon Cancer Test
April 17, 2013 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter - Genomic Health Study Highlights Discrepancy between Oncotype DX and MammaPrint Results
December 19, 2012 / Pharmacogenomics Reporter